BMK vs. INDV, AMYT, AGY, APH, BXP, ANCR, EAH, DNL, CEL, and STX
Should you be buying Benchmark stock or one of its competitors? The main competitors of Benchmark include Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), ECO Animal Health Group (EAH), Diurnal Group (DNL), Celadon Pharmaceuticals (CEL), and Shield Therapeutics (STX). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Indivior (LON:INDV) and Benchmark (LON:BMK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.
Indivior has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, Benchmark has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
In the previous week, Indivior had 11 more articles in the media than Benchmark. MarketBeat recorded 12 mentions for Indivior and 1 mentions for Benchmark. Benchmark's average media sentiment score of 0.40 beat Indivior's score of 0.00 indicating that Indivior is being referred to more favorably in the media.
Indivior received 321 more outperform votes than Benchmark when rated by MarketBeat users. Likewise, 80.38% of users gave Indivior an outperform vote while only 72.62% of users gave Benchmark an outperform vote.
Indivior presently has a consensus price target of GBX 2,100, suggesting a potential upside of 112.77%. Given Benchmark's higher possible upside, equities research analysts clearly believe Indivior is more favorable than Benchmark.
Indivior has higher revenue and earnings than Benchmark. Benchmark is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Indivior has a net margin of 0.44% compared to Indivior's net margin of -18.96%. Benchmark's return on equity of 12.20% beat Indivior's return on equity.
85.6% of Indivior shares are owned by institutional investors. Comparatively, 91.8% of Benchmark shares are owned by institutional investors. 3.3% of Indivior shares are owned by company insiders. Comparatively, 5.8% of Benchmark shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Indivior beats Benchmark on 13 of the 17 factors compared between the two stocks.
Get Benchmark News Delivered to You Automatically
Sign up to receive the latest news and ratings for BMK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BMK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Benchmark Competitors List
Related Companies and Tools
Free BMK Stock Alerts